Comparative Study of Low-dose Pioglitazone or Metformin Treatment in Japanese Diabetic Patients with Metabolic Syndrome
| Autor: | K. Yamada, Naoyuki Katada, F. Taki, Yoshikuni Sawai, T. Kato, Nobuki Hayakawa, T. Terabayashi, Atsushi Suzuki, Hitoshi Kanayama, Mitsuyasu Itoh, H. Taguchi, Naohisa Oda, Y. Yamazaki |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Blood Glucose Male medicine.medical_specialty endocrine system diseases Endocrinology Diabetes and Metabolism Radioimmunoassay Urology Blood Pressure Body Mass Index chemistry.chemical_compound Endocrinology Heart Rate Internal medicine Heart rate Internal Medicine Humans Medicine Pulse wave velocity Aged Ultrasonography Glycated Hemoglobin Metabolic Syndrome Pioglitazone Triglyceride business.industry Patient Selection nutritional and metabolic diseases General Medicine Middle Aged medicine.disease Metformin C-Reactive Protein Treatment Outcome Postprandial Blood pressure Diabetes Mellitus Type 2 chemistry Female Thiazolidinediones Waist Circumference Metabolic syndrome business medicine.drug |
| Zdroj: | Experimental and Clinical Endocrinology & Diabetes. 117:593-599 |
| ISSN: | 1439-3646 0947-7349 |
| Popis: | The aim of this study was to determine whether a relatively low dose of pioglitazone or metformin was effective in diabetic patients with metabolic syndrome. Fifty diabetic patients with metabolic syndrome were randomly assigned to a low-dose pioglitazone (15 mg/day) treatment group or a low-dose metformin (500 mg/day) treatment group. Drugs were administered for 12 weeks. Systolic and diastolic blood pressure, heart rate, body mass index, triglyceride (TG), HDL and LDL-cholesterol, fasting plasma glucose (FPG), fasting plasma insulin (IRI), postprandial glucose, and HOMA-IR in the 75gOGTT, HbA1c, high-sensitivity CRP (hs-CRP) determined by cervical artery echography, and pulse wave velocity (PWV) were measured before/after 12-week drug administration. Significant decreases in HbA1c and HOMA-IR were noted in the pioglitazone group, along with significant decreases in TG, AST, ALT, blood pressure, hs-CRP and PWV. Significant decreases in HbA1c, HOMA-IR, BMI and waist circumference were noted in the metformin group. The pioglitazone group significantly improved the values for ALT, systolic blood pressure, hs-CRP and PWV compared to the metformin group. However, the metformin group demonstrated significant improvement in BMI compared with the pioglitazone group. Using a low dose regimen, pioglitazone significantly improved blood pressure and hepatic function and may be more effective than metformin to reduce risk factors in Japanese diabetic patients with metabolic syndrome at preventing atherosclerosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|